Trial Profile
A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade (Deferasirox) (The MILE Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- Acronyms MILE
- Sponsors Novartis
- 01 Feb 2017 Primary endpoint (Change in cardiac iron load and cardiac ejection fraction by MRI recorded at baseline and after 53 weeks.) has been met as per results published in the European Journal of Haematology
- 01 Feb 2017 Results published in the European Journal of Haematology
- 11 Mar 2016 New trial record